Diese Webseite verwendet Cookies

Diese Seite verwendet Cookies, um Ihnen dieses Angebot leicht zugänglich zu machen, Inhalte zu personalisieren, Ihre Zugriffe auf die Webseite zu analysieren und Ihnen ggf. personalisierte Angebote unterbreiten zu können. Hierzu kann es notwendig sein, dass die Informationen über Ihre Verwendung der Webseite an Partner weitergegeben werden. Diese führen die gesammelten Informationen möglicherweise mit weiteren Daten zusammen, die Sie an anderer Stelle bereitgestellt haben. Eine Weitergabe erfolgt dabei aber nur mit Ihrer Einwilligung und unter Beachtung der datenschutzrechtlichen Vorgaben. Weiterführende Informationen über die hier verwendeten Cookies erfahren Sie in den folgenden Erklärungen zu den jeweiligen Cookies.

Notwendige Cookies helfen dabei, Ihnen die Funktionen der Webseite zugängig zu machen, indem sie Grundfunktionen die zuletzt angesehen Wertpapiere und Ihre Entscheidung für oder gegen die Nutzung der jeweiligen Cookies speichert. Die Webseite wird ohne diese Cookies nicht so funktionieren, wie es geplant ist.

Name Anbieter Zweck Ablauf Typ Verantwortlicher
CookieConsent3434 Moneyspecial Um diese Cookiebar auszublenden. 1 Jahr http Infront Financial Technology GmbH
Die Cookie-Erklärung wurde das letzte Mal am 21.08.2020 von Infront Financial Technology GmbH aktualisiert.
Drucken

MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.

To develop the first-ever mechatronic Shape Memory Alloy Guidewire, improving endovascular access & navigation, during minimally invasive procedures

PARIS & NEW YORK --(BUSINESS WIRE)-- 13.12.2023 --

BCV announced today that the company has secured €6 million in a Series A round of financing led by New-York based Forepont Capital Partners, an international venture capital firm investing in disruptive biotech & medtech start-ups. Other investors include Palo Alto based NTI, France based MEDCO and existing French investors. This Series A funding brings the total amount raised since inception to €13M. BCV's Series A remains open until March 31st 2024.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231212234279/en/

"Forepont is proud to lead BCV's series A raise to support the advancement of BCV's superior technology that has already been endorsed by over 100 international interventional radiology experts in the US and in Europe," says Frederic Batoua, a Partner at Forepont Capital partners.

"Our technology, applied to a guidewire, will be a disruptive change in minimally invasive procedures improving patients' outcomes," says Raphaël Blanc, M.D., Chairman & Co-Founder, BCV.

The funding will accelerate the development of BCV's range of active mechatronic1 guidewires, from manufacturing to go-to-market. BCV has already built a plant in Reims to secure in-house manufacturing and R&D evolution toward miniaturization.

"This round of financing will enable BCV to progress toward FDA and CE mark approval," adds Thierry Col, CEO, BCV. "Forepont and NTI will accelerate BCV's development first in the US market thanks to a premier network in endovascular access," concludes Thierry Col.

The patented innovation consists of an actuable2 guidewire controlled by a smart handle and a generator. The BCV system's shape-memory alloy technology enables distal tip control improving practitioners' gestures and demonstrating superior performance over existing advanced actuation technologies.

"BCV creates an opportunity to simplify and speed up access in complicated anatomies, a critical part of all endovascular procedures," as Adnan H. Siddiqui, MD, PhD, FACS, FAHA (USA) underlines.

This steerable mechatronic guidewire is designed to enhance safety, reduce procedure time and produce better outcomes, providing support during critical interventions performed for stroke or artery diseases.

About BCV
BCV is a medical device company founded in 2016 with the mission to improve patient outcomes by providing optimized navigation for endovascular procedures. The company successfully achieved its first in-human clinical trial in 2022 at Rothschild Foundation Hospital in Paris and filed a pre-submission application with the FDA.
Originally developed with help from Institute of Intelligent Systems and Robotics (ISIR) at Sorbonne University-CNRS and INSERM (Paris, France), the core technology is mechatronic. To learn more, please visit www.basecampvascular.com.
Caution: The BCV System is an investigational device and is not available for commercial sale worldwide.

About Forepont
Forepont Capital Partners is a healthcare and life science venture capital firm based in New York with a strong presence in Europe. Forepont has developed partnerships with industry leaders, physicians, key opinion leaders, universities, hospitals and pharmaceutical groups, mainly in neurology. Forepont invest in early-stage companies whose science and technology are intended to positively impact the lives of patients. Forepont provides scientific, technological, financial and operational support to improve portfolio company performance, leveraging their talents with its know-how and global ecosystem.

About NTI
Neurotechnology Investors is composed of physicians from around the world with backgrounds in neurosurgery, neurology, and several vascular specialties. NTI draws on the collective knowledge of its membership to identify, invest, and provide operational expertise for promising medical technologies along their development lifecycle, from concept through commercialization.

_________________________________________________________________________

1 Mechatronic: both mechanical and electronic.
2 Actuable: the ability to be put into mechanical action or motion.

Delphine BOULAIRE SALVIO (BCV) delphine@basecampvascular.com
Martine Pain-Lacoste (FCP - Aplus Communication / Forepont) martine.pain@agence-aplus.fr

Business Wire

Zeit Meldung
21.06. BUSINESS WIRE: QpiAI schließt 6,5 Millionen Dollar
21.06. BUSINESS WIRE: Takeda Receives Approval from Europ
21.06. BUSINESS WIRE: Vertex Announces Positive Results F
21.06. BUSINESS WIRE: Norwegisches Naturwunder Trolltunga
21.06. BUSINESS WIRE: Biocytogen erhält US-Patent für sei
21.06. BUSINESS WIRE: Hanshow präsentiert auf der Interso
21.06. BUSINESS WIRE: Melodia Therapeutics und Alivexis u
21.06. BUSINESS WIRE: Kolmar BNH schärft globale Wettbewe
21.06. BUSINESS WIRE: Njord Partners veräußert SolidAl an
21.06. BUSINESS WIRE: Slate Asset Management Completes Ap
21.06. BUSINESS WIRE: Cinemo Partners With NIO to Bring H
21.06. BUSINESS WIRE: MSCI gibt die Ergebnisse der MSCI 2
21.06. BUSINESS WIRE: Innovative Netzverstärkungstechnolo
21.06. BUSINESS WIRE: teamLab Borderless Jeddah | Das rek
21.06. BUSINESS WIRE: QPS stellt neue Leitung der globale
21.06. BUSINESS WIRE: GIST Impact, ein führender Anbieter
21.06. BUSINESS WIRE: ASTRA 1P erfolgreich an Bord einer
21.06. BUSINESS WIRE: Mit dem Lenovo Tab Plus, dem Traum-
21.06. BUSINESS WIRE: Mary Kay Inc. präsentiert neue Erke
20.06. BUSINESS WIRE: Laut unabhängiger weltweiter Umfrag
20.06. BUSINESS WIRE: Oxford Global Resources erweitert S
20.06. BUSINESS WIRE: PLIDCO® erhält bei der OTC die Ausz
20.06. BUSINESS WIRE: Die Dennemeyer Group wählt Talkdesk
20.06. BUSINESS WIRE: Westlake Epoxy erhält Gold-Bewertun
20.06. BUSINESS WIRE: Treten Sie ein in die Zukunft des H

Mehr Marktdaten und Kurse finden Sie auf www.finanztreff.de

Angebote der
Nutzungshinweise | Datenschutz | Impressum | Datenquellen: boerse-stuttgart.de,